GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.
GlaxoSmithKline (GSK) and Amicus Therapeutics have revised their drug-development under which Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Under the terms of the revised agreement:
Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCl co-formulated with ERT) as well as migalastat HCl monotherapy
GSK will be eligible for future regulatory and commercial milestone payments, as well as royalty payments.
GSK will further invest $3 million in Amicus through an equity investment in a concurrent private placement in public equity (PIPE) transaction
